The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers.
Epizyme also announced the publication of 10 patent applications covering chemical matter targeting several additional HMTs: CARM1, PRMT1, PRMT3, PRMT6 and PRMT8. These additional HMT targets are implicated in a variety of solid tumors and hematologic malignancies.
"These notices of allowance and publications further solidify our leadership position in the HMT space, and we continue to advance our dominant intellectual property position. Epizyme now has patents and patent applications for 13 of the 20 prioritized targets that comprise the Company’s pioneering HMT platform, covering therapeutic and diagnostic methods, combination therapy methods and pharmaceutical compositions," said Robert Gould, Ph.D., President and Chief Executive Officer, Epizyme.
"We believe these patents and pending applications place us in the strongest possible position to build our company over the long-term and accelerate our efforts to bring life-saving drugs to patients."